PRA Health Sciences (PRAH) Downgraded to Hold at Zacks Investment Research
PRA Health Sciences (NASDAQ:PRAH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “PRA Health Sciences, Inc. operates as a global contract research organizations providing outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in the areas of cardio-metabolic, biosimilars, infectious diseases, immunology, neurology and psychiatry, oncology and hematology, rare diseases, and respiratory needs. The Company engages in bioanalytical laboratory, clinical pharmacology, clinical development, strategic solutions, post marketing research, clinical informatics, clinical diagnostics, and safety and risk management activities. PRA Health Sciences, Inc. is based in Raleigh, North Carolina. “
Several other brokerages have also commented on PRAH. Mitsubishi UFJ Financial Group started coverage on PRA Health Sciences in a report on Friday, December 15th. They issued an “overweight” rating and a $102.00 price objective on the stock. Credit Suisse Group reissued an “outperform” rating and issued a $90.00 price objective (up from $84.00) on shares of PRA Health Sciences in a report on Monday, October 16th. BidaskClub raised PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 27th. Mizuho started coverage on PRA Health Sciences in a report on Thursday, September 21st. They issued a “buy” rating and a $82.00 price objective on the stock. Finally, Jefferies Group reissued a “buy” rating and issued a $95.00 price objective on shares of PRA Health Sciences in a report on Thursday, October 26th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $91.85.
PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, beating the consensus estimate of $0.85 by $0.03. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. The company had revenue of $494.55 million for the quarter, compared to analyst estimates of $477.89 million. During the same period last year, the company earned $0.64 earnings per share. PRA Health Sciences’s quarterly revenue was up 23.7% compared to the same quarter last year. analysts anticipate that PRA Health Sciences will post 3.2 earnings per share for the current fiscal year.
In other PRA Health Sciences news, Director Matthew P. Young sold 5,115 shares of the business’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider David W. Dockhorn sold 72,850 shares of the business’s stock in a transaction on Thursday, December 28th. The stock was sold at an average price of $90.83, for a total value of $6,616,965.50. The disclosure for this sale can be found here. Insiders sold 150,815 shares of company stock worth $13,642,620 over the last ninety days. Corporate insiders own 2.10% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in PRA Health Sciences by 28.2% during the second quarter. BlackRock Inc. now owns 3,662,954 shares of the medical research company’s stock worth $274,759,000 after buying an additional 805,573 shares during the last quarter. Capital Research Global Investors boosted its stake in PRA Health Sciences by 318.3% during the second quarter. Capital Research Global Investors now owns 2,175,340 shares of the medical research company’s stock worth $163,172,000 after buying an additional 1,655,336 shares during the last quarter. Wells Fargo & Company MN boosted its stake in PRA Health Sciences by 55.8% during the third quarter. Wells Fargo & Company MN now owns 1,207,069 shares of the medical research company’s stock worth $91,943,000 after buying an additional 432,449 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in PRA Health Sciences by 3.4% during the third quarter. Russell Investments Group Ltd. now owns 915,111 shares of the medical research company’s stock worth $69,704,000 after buying an additional 29,771 shares during the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in PRA Health Sciences by 5.7% during the third quarter. Ameriprise Financial Inc. now owns 834,034 shares of the medical research company’s stock worth $63,528,000 after buying an additional 45,227 shares during the last quarter. 98.23% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/pra-health-sciences-prah-downgraded-to-hold-at-zacks-investment-research/1812302.html.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.